tirzepatide and bipolar disorder for the Maintenance of Body Weight Reduction: Rationale, Design, Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide and Depression Risk |

As of early 2026, retatrutide is in Phase 3 clinical trials and has not yet received FDA approval

When in doubt, do not inject it

By optimizing deep sleep, individuals may experience improved cognitive function, enhanced physical recovery, and increased overall well-being

CMS has historically interpreted the Medicare prohibition to mean that Part D plans could not cover obesity medications, creating a significant gap in care for older Americans with obesity

Because the mineral doses in this specific formula are relatively low and well-balanced, the risk of mineral toxicity is minimal when taken at standard suggested doses (1-4 capsules daily)